stockrow60 Degrees Pharmaceuticals Inc.
SXTP Healthcare Biotechnology
60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024.
- Revenue
- −32.5%
- EPS
- +82.0%
- Free cash flow
- −54.3%
Quarter to June 2026, against a year earlier
Follow SXTP
Alert me
60 Degrees Pharmaceuticals Inc. (SXTP) EV/Sales
As of 6 November 2026, 60 Degrees Pharmaceuticals Inc. (SXTP) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from −4.5× (October 2024) to 28.0× (July 2023); the current reading is higher than 45% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.1× | — |
| FY2024 | 1.1× | (94.36%) |
| FY2023 | 20.1× | (28.08%) |
| FY2022 | 28.0× | 0.00% |
| FY2021 | 28.0× | 0.00% |
| FY2020 | 28.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.0× | 483.61% |
| Mar 2026 | 0.7× | — |
| Dec 2025 | −0.1× | — |
| Sep 2025 | 1.9× | (33.09%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIPO Lipella Pharmaceuticals Inc. compare | −3.3× |
| TRAW Traws Pharma, Inc. compare | −0.5× |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. | 1.5× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 8.7× |
| ONCO Onconetix, Inc. compare | 14.6× |
| ERNA Ernexa Therapeutics Inc. compare | 50.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)